RU2018101989A - Композиции и способы для усиления нейрогенеза у животных - Google Patents

Композиции и способы для усиления нейрогенеза у животных Download PDF

Info

Publication number
RU2018101989A
RU2018101989A RU2018101989A RU2018101989A RU2018101989A RU 2018101989 A RU2018101989 A RU 2018101989A RU 2018101989 A RU2018101989 A RU 2018101989A RU 2018101989 A RU2018101989 A RU 2018101989A RU 2018101989 A RU2018101989 A RU 2018101989A
Authority
RU
Russia
Prior art keywords
vitamin
animal
composition
group
neurogenesis
Prior art date
Application number
RU2018101989A
Other languages
English (en)
Other versions
RU2018101989A3 (ru
RU2735834C2 (ru
Inventor
Юанлонг ПАН
Original Assignee
Нестек Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56296871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018101989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нестек Са filed Critical Нестек Са
Publication of RU2018101989A publication Critical patent/RU2018101989A/ru
Publication of RU2018101989A3 publication Critical patent/RU2018101989A3/ru
Application granted granted Critical
Publication of RU2735834C2 publication Critical patent/RU2735834C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)

Claims (24)

1. Способ усиления нейрогенеза у животного, включающий:
идентификацию животного, которое страдает снижением когнитивных способностей, которое подвержено риску нарушения когнитивных функций, у которого диагностировано заболевание, расстройство или другое состояние, влияющее на его когнитивные способности, или которое подвержено риску развития заболевания, расстройства или другого состояния, влияющего на когнитивные способности, и
введение животному композиции, содержащей ненасыщенную жирную кислоту (НЖК), выделяющее оксид азота соединение (ВОАС), витамин группы B и антиоксидант, причем композицию вводят в количестве, эффективном для усиления нейрогенеза у животного.
2. Способ по п. 1, в котором нейрогенез происходит в гиппокампе животного и плотность нейронов повышается по меньшей мере на 10%.
3. Способ по п. 1, в котором композиция содержит от приблизительно 0,1% до приблизительно 50% НЖК, причем НЖК представляет собой одно или более из натурального рыбьего жира, ALA, EPA, DPA, DHA или другой n-3 жирной кислоты из любого источника.
4. Способ по п. 1, в котором композиция содержит от приблизительно 0,1% до приблизительно 20% ВОАС, причем ВОАС представляет собой аргинин, цитруллин, орнитин или их производное, выделяющее оксид азота.
5. Способ по п. 1, в котором композиция содержит витамин группы B в количестве, превышающем рекомендуемую суточную потребность приблизительно в 1,2–40 раз, причем витамин группы B выбирают из группы, состоящей из витамина B1, витамина B2, витамина B3, витамина B5, витамина B6, витамина B7, витамина B8, витамина B9, витамина B12 и их смесей.
6. Способ по п. 1, в котором композиция содержит от приблизительно 0,0001% до приблизительно 25% антиоксиданта, причем антиоксидант выбирают из любой группы, состоящей из каротиноидов, флавоноидов, фенольных кислот и их сложных эфиров, нефлавоноидных фенольных смол, куркумина, флавонолигнанов, ксантонов, эвгенола, витамина C, витамина E, селена и их смесей.
7. Способ по п. 1, в котором композиция составлена в виде пищевой композиции для человека, композиции корма для домашних животных или диетической добавки.
8. Способ по п. 1, в котором животное имеет фенотип, связанный с возрастным нарушением когнитивных функций, причем фенотип включает одно или более из пониженной способности к припоминанию, потери кратковременной памяти, пониженной скорости обучения, пониженной восприимчивости к обучению, пониженной способности к решению проблем, пониженной продолжительности концентрации внимания, пониженной двигательной активности, повышенной дезориентации во времени и в пространстве или деменции по сравнению с контрольным животным, не имеющим такого фенотипа.
9. Способ по п. 1, в котором животное является здоровым стареющим животным.
10. Способ по п. 1, в котором животное представляет собой животное из семейства собачьих или кошачьих.
11. Способ усиления нейрогенеза у растущего животного, включающий:
идентификацию растущего животного и
введение растущему животному композиции, содержащей ненасыщенную жирную кислоту (НЖК), выделяющее оксид азота соединение (ВОАС), витамин группы B и антиоксидант, причем композицию вводят в количестве, эффективном для усиления нейрогенеза у растущего животного.
12. Способ по п. 11, в котором нейрогенез происходит в гиппокампе растущего животного и плотность нейронов повышается по меньшей мере на 10%.
13. Способ по п. 11, в котором композиция содержит от приблизительно 0,1% до приблизительно 50% НЖК, причем НЖК представляет собой одно или более из натурального рыбьего жира, ALA, EPA, DPA, DHA или другой n-3 жирной кислоты из любого источника.
14. Способ по п. 11, в котором композиция содержит от приблизительно 0,1% до приблизительно 20% ВОАС, причем ВОАС представляет собой аргинин, цитруллин, орнитин или их производное, выделяющее оксид азота.
15. Способ по п. 11, в котором композиция содержит витамин группы B в количестве, превышающем рекомендуемую суточную потребность приблизительно в 1,2–40 раз, причем витамин группы B выбирают из группы, состоящей из витамина B1, витамина B2, витамина B3, витамина B5, витамина B6, витамина B7, витамина B8, витамина B9, витамина B12 и их смесей.
16. Способ по п. 11, в котором композиция содержит от приблизительно 0,0001% до приблизительно 25% антиоксиданта, причем антиоксидант выбирают из любой группы, состоящей из каротиноидов, флавоноидов, фенольных кислот и их сложных эфиров, нефлавоноидных фенольных смол, куркумина, флавонолигнанов, ксантонов, эвгенола, витамина C, витамина E, селена и их смесей.
17. Способ по п. 11, в котором композиция составлена в виде пищевой композиции для человека, композиции корма для домашних животных или диетической добавки.
18. Способ по п. 11, в котором растущее животное достигло от 0 до 30% ожидаемой продолжительности жизни.
19. Способ по п. 11, в котором растущее животное представляет собой младенца, котенка или щенка.
20. Способ по п. 11, в котором композиция включает аргинин, рыбий жир, витамины группы B, витамин E, витамин C, астаксантин и селен.
RU2018101989A 2015-06-22 2016-06-21 Композиции и способы для усиления нейрогенеза у животных RU2735834C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562182922P 2015-06-22 2015-06-22
US62/182,922 2015-06-22
US201562205937P 2015-08-17 2015-08-17
US62/205,937 2015-08-17
PCT/IB2016/053689 WO2016207794A1 (en) 2015-06-22 2016-06-21 Compositions and methods for enhancing neurogenesis in animals

Publications (3)

Publication Number Publication Date
RU2018101989A true RU2018101989A (ru) 2019-07-22
RU2018101989A3 RU2018101989A3 (ru) 2019-12-06
RU2735834C2 RU2735834C2 (ru) 2020-11-09

Family

ID=56296871

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018101989A RU2735834C2 (ru) 2015-06-22 2016-06-21 Композиции и способы для усиления нейрогенеза у животных

Country Status (11)

Country Link
US (1) US20160367509A1 (ru)
EP (1) EP3310349B1 (ru)
JP (1) JP6820868B2 (ru)
CN (1) CN107708446A (ru)
AU (1) AU2016281870B2 (ru)
BR (1) BR112017025664A2 (ru)
CA (1) CA2987033C (ru)
ES (1) ES2860427T3 (ru)
MX (1) MX2017015973A (ru)
RU (1) RU2735834C2 (ru)
WO (1) WO2016207794A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017025664A2 (pt) 2015-06-22 2018-08-07 Nestec Sa composições e métodos para aumentar a neurogênese em animais
JP2019530665A (ja) 2016-09-29 2019-10-24 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 認知症ではない患者における神経保護薬としての、ω３脂肪酸及びコリン
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2019010484A (es) * 2017-04-11 2019-10-17 Nestle Sa Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.
WO2018188771A1 (en) * 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
EP3388061A1 (en) * 2017-04-11 2018-10-17 Nestec S.A. Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
GR20170100368A (el) * 2017-08-04 2019-04-22 Νικολετα Ανδρεα Τουμαζατου Μπισκοτα υπερτροφης ανθρωπων και σκυλων
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US20210186054A1 (en) * 2019-12-19 2021-06-24 Société des Produits Nestlé S.A. Compositions and methods for providing a health benefit to a growing animal
FR3135876B3 (fr) * 2022-05-25 2024-05-24 Nestle Sa Compositions et procédés pour mélanges d’aliments déshydratés pour animaux de compagnie
CN116268228B (zh) * 2022-12-23 2024-06-18 广西中医药大学 一种海马配合饲料及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310772B (zh) 1999-06-14 2012-02-08 亨利福特保健系统公司 用于诱导神经发生的氧化氮供体
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
JP2003261456A (ja) 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
DK1583541T3 (da) * 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
WO2006090745A1 (ja) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. 神経再生促進剤
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
JP5931337B2 (ja) 2007-10-04 2016-06-08 ネステク ソシエテ アノニム 認知機能を高める組成物及び方法
RU2500402C2 (ru) * 2008-01-04 2013-12-10 Нестек С.А. Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функций
RU2606841C2 (ru) 2010-09-03 2017-01-10 Н.В. Нютрисиа Способ и препарат для лечения или профилактики тревожности или нейрогенеза
WO2012083034A1 (en) 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US9351978B2 (en) 2012-02-29 2016-05-31 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
BR112017025664A2 (pt) 2015-06-22 2018-08-07 Nestec Sa composições e métodos para aumentar a neurogênese em animais

Also Published As

Publication number Publication date
AU2016281870B2 (en) 2020-09-10
CA2987033A1 (en) 2016-12-29
EP3310349A1 (en) 2018-04-25
MX2017015973A (es) 2018-04-20
CA2987033C (en) 2023-11-28
US20160367509A1 (en) 2016-12-22
BR112017025664A2 (pt) 2018-08-07
JP6820868B2 (ja) 2021-01-27
WO2016207794A1 (en) 2016-12-29
JP2018528160A (ja) 2018-09-27
AU2016281870A1 (en) 2017-11-23
ES2860427T3 (es) 2021-10-05
EP3310349B1 (en) 2021-01-13
CN107708446A (zh) 2018-02-16
RU2018101989A3 (ru) 2019-12-06
RU2735834C2 (ru) 2020-11-09

Similar Documents

Publication Publication Date Title
RU2018101989A (ru) Композиции и способы для усиления нейрогенеза у животных
Alagawany et al. Nutritional significance and health benefits of designer eggs
Roo et al. Effect of DHA content in rotifers on the occurrence of skeletal deformities in red porgy Pagrus pagrus (Linnaeus, 1758)
Skřivan et al. The deposition of carotenoids and α-tocopherol in hen eggs produced under a combination of sequential feeding and grazing
BR112018072064A2 (pt) composições nutricionais para proteção cardíaca em animais de estimação
Yannakopoulos et al. Enhanced egg production in practice: the case of bio-omega-3 egg
Boiago et al. Spirulina platensis in Japanese quail feeding alters fatty acid profiles and improves egg quality: Benefits to consumers
Simitzis et al. Agroindustrial by-products and animal products: A great alternative for improving food-quality characteristics and preserving human health
Álvarez-Rodríguez et al. Insights into the role of major bioactive dietary nutrients in lamb meat quality: A review
Szczerbińska et al. Effect of the diet with common flax (Linum usitatissimum) and black cumin seeds (Nigella sativa) on quail performance and reproduction.
KR20140116482A (ko) Dha 및 epa를 포함하는 유기 유화액
ES2882107T3 (es) Aumentar el contenido de ácidos grasos esenciales de los huevos mediante la suplementación nutricional de los animales utilizando una dosis muy baja de un extracto vegetal rico en flavonoides
WO2016083853A1 (en) Olive-based dietary method for pigs
Jameel Effect of the content of fish oil, L-carnitine and their combination in diet on immune response and some blood parameters of broilers
Nguyen et al. Influence of dietary fat sources on growth, bacterial resistance, and antioxidant ability of liver in common carp, Cyprinus carpio
Andri et al. Effect of fish oil alone or in combination with tomato powder supplementation in feed on egg quality of local ducks
Cabana et al. Supporting Geriatric Zoo Animal Welfare Through Nutrition
Saadoun New approaches on the importance of fatty acids in poultry meat on human health
Aminikhoei The use of algae in the diet and improving the color of ornamental
Abbas et al. CONSUMER PREFERENCES AND MARKET TRENDS: CUSTOMIZING POULTRY PRODUCTS FOR CUSTOMER-BASED POULTRY MARKETS
CN106727229A (zh) 海藻美毛膏
RU2662202C1 (ru) Способ получения пищевых яиц, обогащенных полиненасыщенными жирными кислотами
Safari et al. Antioxidant and immune gene expression in zebra fish (Danio rerio)
Andri et al. Effects of Fish Oil and Tomato Powder Supplementation in Mojosari Ducks Diet on Egg Quality
Chartrin et al. Effect of different dietary sources of n-3 fatty acids on the laying performance and technological, nutritional and sensorial quality of eggs.

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant